Editorial Epublish
PubMed: 42495470 DOI: 10.7759/cureus.111342
Navigating NTRK in Non-small Cell Lung Cancer (NSCLC): A Patient Perspective.
Cureus 18(6):e111342
Authors: Justin Gainor, Leah Bundy, Stevan Bradford
Affiliations
- Center for Thoracic Cancers, Massachusetts General Hospital, Boston, USA.
- Medicine, Springer Health+ IME, London, GBR.
- Patient author, N/A, Calvert, USA.
Abstract
NTRK fusion-positive non-small cell lung cancer (NSCLC) represents a rare molecular subtype in which effective clinician-patient communication and an understanding of the lived experience are essential to supporting personalized care. This podcast presents a video interview exploring experiences associated with NTRK fusion-positive NSCLC, examining key stages of the diagnostic and treatment pathway, including biomarker testing, the emotional impact of diagnosis, initiation of targeted therapy, and managing treatment-related adverse events. It also considers the psychological impact of NTRK fusion-positive NSCLC, including the emotional burden of diagnosis, challenges of independently seeking information about rare alterations, treatment delays, and the transition from chemotherapy to a targeted therapeutic approach. Emphasis is placed on the importance of timely biomarker testing and transparent communication around biomarker testing and treatment timelines, as well as greater clinical recognition of the uncertainty often experienced by individuals with rare genomic alterations. By amplifying the patient voice, this piece seeks to foster greater awareness and empathy among healthcare professionals and contribute to improved outcomes in precision oncology.
MeSH
Cells, Research Design, Lung, Communication, Neoplasms, Carcinoma, Non-Small-Cell Lung, Biomarkers, Lung Neoplasms, Small Cell Lung Carcinoma, Diagnosis, Therapeutics